ДИАГНОСТИКА И СТАДИРОВАНИЕ РАКА МОЧЕВОГО ПУЗЫРЯ

Рак мочевого пузыря (РМП) является достаточно распространенной патологией в  структуре онкологической заболеваемости как в мире, так и в Российской Федерации, особенно у пожилых пациентов. Как известно, показатели 5-летней выживаемости и безрецидивного периода напрямую коррелируют со стадией опухолевого процесса, что определяет значимость адекватной оценки распространенности новообразований при планировании тактики лечения. В  статье представлен обзор научных работ, посвященных методам визуализации, которые используются для предоперационного стадирования РМП. В настоящее время наибольший интерес представ- ляет мультипараметрическая МРТ, обладающая рядом преимуществ перед другими методами визуализации, включая неинвазивность, высокую тканевую и пространственную визуализацию, а также отсутствие ионизи- рующего излучения. Появление данного метода способствовало повышению диагностической эффективности при оценке распространенности РМП. Однако сохраняется ряд нерешенных вопросов, связанных с ошибками интерпретации глубины инвазии и оценки зон регионарного лимфооттока, которые требуют детального изучения и анализа.

1. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность) / под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: МНИО им. П. А. Герцена — филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 250 с. [Zlokachestvennye novoobrazovaniya v Rossii v 2015 godu (zabolevaemost’ i smertnost’) / pod red. A. D. Kaprina, V. V. Starinskogo, G. V. Petrovoj. Moscow: MNIO im. P. A. Gercena — filial FGBU «NMIRC» Minzdrava Rossii, 2017, 250 р. (In Russ.)].

2. Malats N., Real F.X. Epidemiology of bladder cancer. Hematol. Oncol., Clin. North Am, 2015, vol. 29, No. 2, рр. 177–189.

3. Miyamoto H., Miller J.S., Fajardo D.A. et al. Non-invasive papillary urothelial neoplasms: The 2004 WHO/ISUP classification system. Pathol. Int., 2010, vol. 60, No. 1, рр. 1–8.

4. Kundra V., Silverman P.M. Imaging in oncology from the University of Texas M.D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR, 2003, Vol. 180, No. 4, рр. 1045–1054.

5. Yoshida S. Diffusion-weighted magnetic resonance imaging in management of bladder cancer, particularly with multimodal bladder-sparing strategy. World J. Radiol., 2014, vol. 6, No. 6, рр. 344.

6. Kassouf W., Traboulsi S. L., Schmitz-Dräger B. et al. Follow-up in non-muscle-invasive bladder cancer- International Bladder Cancer Network recommendations. Urol. Oncol., 2016, Vol. 34, No. 10, рр. 460–468.

7. Mowatt G., Zhu S., Kilonzo M. et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology volfor the detection and follow-up of bladder cancer. Health Technol. Assess, 2010, Vol. 14, No. 4, рр. 1–331.

8. Liu J.J, Droller M.J., Liao J.C. New optical imaging technologies for bladder cancer: considerations and perspectives. J. Urol., 2012, Vol. 188, No. 2, рр. 361–368.

9. Schmidbauer J., Witjes F., Schmeller N. et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J. Urol., 2004, Vol. 171, No. 1, рр. 135–138.

10. Burger M., Grossman H., Droller M. et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur. Urol., 2013, Vol. 64, No. 5, рр. 846–854.

11. Jocham D., Stepp H., Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur. Urol., 2008, Vol. 53, No. 6, рр. 1138–1148.

12. Halling K.C., King W., Sokolova I.A. et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J. Urol., 2000, Vol. 164, No. 5, рр. 1768–1775.

13. Lotan Y., Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology, 2003, Vol. 61, No. 1, рр. 109–118.

14. Yafi F.A., Brimo M., Auger M. et al. Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer. Urol. Oncol., 2014, Vol. 32, No. 1, рр. 27.e1–27.e6.

15. Liou L.S. Urothelial cancer biomarkers for detection and surveillance. Urology, 2006, Vol. 67, No. 3, рр. 25–33.

16. Van Rhijn B.W.G., Van Der Poel H.G., Van Der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur. Urol., 2005, Vol. 47, No. 6, рр. 736–748.

17. Schmitz-Dräger B.J., Droller M., Lokeshwar V. et al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD Consensus. Urol. Int., 2015, Vol. 94, No. 1, рр. 1–24.

18. Kamat A.M., Karam J.A., Grossman H.B. et al. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int., 2011, Vol. 108, No. 7, рр. 1119–1123.

19. Schmitz-Dräger B.J., Kuchuck E.C., Zuiverloon T.C.M. et al. Microhematuria assessment an IBCN consensus- based upon a critical review of current guidelines. Urol. Oncol.,, 2016, Vol. 34, No. 10, рр. 437–451.

20. Hafeez S., Huddart R. Advances in bladder cancer imaging. BMC Med., 2013, Vol. 11, No. 1, рр. 104.

21. Macvicar A.D. Bladder cancer staging. BJU Int., 2000, Vol. 86 (Suppl. 1), рр. 111–122.

22. Itzchak Y., Singer D., Fischelovitch Y. Ultrasonographic assessment of bladder tumors. I. Tumor detection. J. Urol., 1981, Vol. 126, No. 1, рр. 31–33.

23. Park H.J., Hong S.S., Kim J.H. et al. Tumor detection and serosal invasion of bladder cancer: role of three-dimensional volumetric reconstructed US. Abdom. Imaging, 2010, Vol. 35, No. 3, рр. 265–270.

24. Li Q., Tang J., He E. et al. Clinical utility of three-dimensional contrast-enhanced ultrasound in the differentiation between noninvasive and invasive neoplasms of urinary bladder. Eur. J. Radiol., 2012, Vol. 81, No. 11, рр. 2936–2942.

25. Nicolau C., Bunesch L., Peri L. et al. Accuracy of contrast-enhanced ultrasound in the detection of bladder cancer. Brit. J. Radiol., 2011, Vol. 84, No. 1008, рр. 1091–1099.

26. Caruso G., Salvaggio G., Campisi A. et al. Bladder tumor staging: comparison of contrast-enhanced and gray-scale ultrasound. AJR, 2010, Vol. 194, No. 1, рр. 151–156.

27. Hillman B.J., Silvert M., Cook G. et al. Recognition of bladder tumors by excretory urography. Radiology, 1981, Vol. 138, No. 2, рр. 319–323.

28. Purysko A.S., Leão Filho H.M., Herts B.R. Radiologic imaging of patients with bladder cancer. Semin. Oncol., 2012, Vol. 39, No. 5, рр. 543–558.

29. McKibben M.J., Woods M.E. Preoperative imaging for staging bladder cancer. Curr. Urol. Rep., 2015, Vol. 16, No. 4, рр. 22.

30. Jinzaki M., Tanimoto A., Shinmoto H. et al. Detection of bladder tumors with dynamic contrast-enhanced MDCT. AJR, 2007, Vol. 188, No. 4, рр. 913–918.

31. Turney B.W., Willatt J.M.G., Nixon D. et al. Computed tomography urography for diagnosing bladder cancer. BJU Int., 2006, Vol. 98, No. 2, рр. 345–348.

32. Sadow C.A., Silverman S.G., O’Leary M.P. et al. Bladder cancer detection with CT urography in an Academic Medical Center. Radiology, 2008, Vol. 249, No. 1, рр. 195–202.

33. Barentsz J.O., Engelbrecht M.R.W., Witjes J.A.M. et al. MR imaging of the male pelvis. Eur. Radiol., 1999, Vol. 9, No. 9, рр. 1722–1736.

34. Tritschler S., Mosler C., Straub J. et al. Staging of muscle-invasive bladder cancer: can computerized tomography help us to decide on local treatment? World J. Urol., 2012, Vol. 30, No. 6, рр. 827–831.

35. Wang L.J., Wong Y.C., Ng K.F. et al. Tumor characteristics of urothelial carcinoma on multidetector computerized tomography urography. J. Urol., 2010, Vol. 183, No. 6, рр. 2154–2160.

36. Lu Y.Y., Chen J.H., Liang J.A. et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: A systemic review and meta-analysis. Eur. J. Radiol., 2012, Vol. 81, No. 9, рр. 2411–2416.

37. Goodfellow H., Viney Z, Hughes P. et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int., 2014, Vol. 114, No. 3, рр. 389–395.

38. Picchio M., Treiber U., Beer A.J. et al. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J. Nucl. Med., 2006, Vol. 47, No. 6, рр. 938–944.

39. DeGrado T.R., Baldwin S.W., Wang S. et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J. Nucl. Med., 2001, Vol. 42, No. 12, рр. 1805–1814.

40. Ahlström H., Malmström P.U., Letocha H. et al. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol. 1996, Vol. 37, No. 2, рр. 180–185.

41. Hricak H., Williams R.D., Spring D.B. et al. Anatomy and pathology of the male pelvis by magnetic resonance imaging. AJR. 1983, Vol. 141, No. 6, рр. 1101–1110.

42. De Haas R.J., Steyvers M.J., Fütterer J.J. Multiparametric MRI of the bladder: ready for clinical rutine? AJR, 2014, vol, 202, No. 6, рр. 1187–1195.

43. Raza S.A., Jhaveri K.S. MR iImaging of urinary bladder carcinoma and beyond. Radiol. Clin. North Amer., 2012, Vol. 50, No. 6, рр. 1085–1110.

44. Tekes A., Kamel I.R., Imam K. et al. MR imaging features of transitional cell carcinoma of the urinary bladder. AJR, 2003, Vol. 180, No. 3, рр. 771–777.

45. Daniel B.L., Shimakawa A., Blum M.R. et al. Single-shot fluid attenuated inversion recovery (FLAIR) magnetic resonance imaging of the bladder. J. Magn. Reson. Imaging, 2000, Vol. 11, No. 6, рр. 673–677.

46. Matsuki M., Inada Y., Tatsugami F. et al. Diffusion-weighted MR imaging for urinary bladder carcinoma: initial results. Eur. Radiol., 2007, Vol. 17, No. 1, рр, 201–204.

47. Abou-El-Ghar M.E., El-Assmy A., Refaie H.F. et al. Bladder cancer: diagnosis with diffusion-weighted MR imaging in patients with gross hematuria. Radiology, 2009, Vol. 251, No. 2, рр. 415–421.

48. Watanabe H., Kanematsu M., Kondo H. et al. Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value? AJR, 2009, Vol. 192, No. 5, рр. 1361–1366.

49. El-Assmy A., Abou-El-Ghar M.E., Mosbah A. et al. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur. Radiol., 2009, Vol. 19, No. 7, рр. 1575–1581.

50. Halefoglu A.M., Sen E.Y., Tanriverdi O. et al. Utility of diffusion-weighted MRI in the diagnosis of bladder carcinoma. Clin. Imaging, 2013, Vol. 37, No. 6, рр. 1077–1083.

51. Wu L.M., Chen X.X., Xu J.R. et al. Clinical value of T2-weighted imaging combined with diffusion-weighted imaging in preoperative T staging of urinary bladder cancer. Acad. Radiol., 2013, Vol, 20, No. 8, рр. 939–946.

52. Takeuchi M., Sasaki S., Ito M. et al. Urinary bladder cancer: diffusion-weighted MR imaging- accuracy for diagnosing T stage and estimating histologic grade. Radiology, 2009, Vol. 251, No. 1, рр. 112–121.

53. Verma S., Rajesh A., Prasad S.R. et al. Urinary bladder cancer: role of MR imaging. Radiographics, 2012, Vol. 32, No. 2, рр. 371–387.

54. Tekes A., Kamel I., Imam K. et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR, 2005, Vol. 184, No. 1, рр. 121–127.

55. Daneshmand S., Ahmadi H., Huynh L.N. et al. Preoperative staging of invasive bladder cancer with dynamic gadolinium-enhanced magnetic resonance imaging: results from a prospective study. Urology, 2012, Vol. 80, No. 6, рр. 1313–1318.

56. Simms M.S., Mann G., Kockelbergh R.C. et al. The management of lymph node metastasis from bladder cancer. Eur. J. Surg. Oncol, 2005, Vol. 31, No. 4, рр. 348–356.

57. Deserno W.M., Harisinghani M.G., Taupitz M. et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology, 2004, Vol. 233, No. 2, рр. 449–456.

58. Birkhäuser F.D., Studer U.E., Froehlich J.M. et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur. Urol., 2013, Vol. 64, No. 6, рр. 953–960.

59. Triantafyllou M., Studer U.E., Birkhäuser F.D. et al. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur. J. Cancer, 2013, Vol. 49, No. 3, рр. 616–624.

60. Saksena M.A., Dahl D.M., Harisinghani M.G. New imaging modalities in bladder cancer. World J. Urol., 2006, Vol. 24, No. 5, рр. 473–480.

61. Vining D.J., Zagoria R.J., Liu K. et al. CT cystoscopy: an innovation in bladder imaging. AJR, 1996, Vol. 166, No. 2, рр. 409–410.

62. Qu X., Huang X., Wu L. et al. Comparison of virtual cystoscopy and ultrasonography for bladder cancer detection: a meta-analysis. Eur. J. Radiol., 2011, Vol. 80, No. 2, рр. 188–197.